Latham & Watkins Advises the Underwriters in Vor Biopharma’s Initial Public Offering

A capital markets team represents the underwriters in the cell therapy company’s offering.

February 05, 2021

Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, has announced the pricing of its initial public offering of 9,828,017 shares of its common stock at a price to the public of US$18.00 per share. The gross proceeds to Vor from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Vor, are expected to be approximately US$176.9 million. In addition, Vor has granted the underwriters a 30-day option to purchase up to an additional 1,474,202 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions. All of the shares of common stock are being offered by Vor.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets deal team led by partners Peter Handrinos and Nathan Ajiashvili, with associates Matthew DeSilva, Victoria McGrath, and MacLane Taggart.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.